Atlas Trials

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Clinical trial NCT00948922 · COMPLETED

Trial details

NCT number
NCT00948922
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2009-06-18
Primary completion
2017-04-20
Enrollment
124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.